A clinician's guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infection
- 21 September 2015
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 63 (2) , 634-643
Abstract
The US Food and Drug Administration has recently approved a number of new direct‐acting antiviral agents for the treatment of chronic hepatitis C virus that have significantly increased the likelihood of a virological cure. These agents are highly effective but present a substantial risk for a host of clinically relevant drug‐drug interactions. These interactions must be considered both when starting and stopping any medication, including over‐the‐counter medications and herbal supplements. These drug‐drug interactions can increase the risk of toxicity or decrease the likelihood of treatment response. Knowledge of these interactions is paramount in optimizing the success of antiviral therapy. Conclusion: In this review we summarize the available data regarding drug‐drug interactions for direct‐acting antiviral agents, the interactions being the most clinically relevant that are currently known; this review is intended to serve as a clinician's guide to understanding and managing these complex interactions. (Hepatology 2016;63:634–643)Keywords
This publication has 13 references indexed in Scilit:
- An Interferon-free Antiviral Regimen for HCV after Liver TransplantationNew England Journal of Medicine, 2014
- Understanding and preventing drug–drug and drug–gene interactionsExpert Review of Clinical Pharmacology, 2014
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 InfectionNew England Journal of Medicine, 2014
- Assessment of Pharmacokinetic Interactions of the HCV Ns5A Replication Complex Inhibitor Daclatasvir with Antiretroviral Agents: Ritonavir-Boosted Atazanavir, Efavirenz and TenofovirAntiviral Therapy, 2013
- Pretransplantation Pharmacokinetic Curves of Tacrolimus in HIV-Infected Patients on Ritonavir-Containing cARTTransplantation, 2013
- ABC Multidrug Transporters: Target for Modulation of Drug Pharmacokinetics and Drug-Drug InteractionsCurrent Drug Targets, 2011
- Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirinJournal of Hepatology, 2008
- Drug Therapy in the Heart Transplant RecipientCirculation, 2005
- Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patientsLiver Transplantation, 2004
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000